147 results about "Bile acid" patented technology

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

The invention belongs to the technical field of biological medicine, and discloses a dry blood spot liquid chromatography-mass spectrometry detection method adaptive to 7 metabolites. According to the method, a pH / polarity double-trigger microcapsule solvent carrier system is adopted, high-polarity extraction solvents, medium-polarity extraction solvents and low-polarity extraction solvents are packaged in the pH / polarity double-trigger microcapsule solvent carrier system in a layered mode, the solvents are released in sequence according to local pH and polarity changes in the extraction process, and amino acid, acyl carnitine, organic acid, bile acid, steroid, fatty acid and glycometabolism intermediate products are efficiently extracted respectively. The method disclosed by the invention breaks through the inherent limitation of a traditional static solvent system, solves the problem of unbalanced recovery rate caused by insufficient solvent suitability in dry blood spot extraction of seven metabolites with great polarity span, and remarkably improves the accuracy, reproducibility and coverage range of a DBS-LC-MS / MS platform in synchronous detection of multi-component metabolites; and reliable technical support is provided for newborn inherited metabolic disease screening, endocrine disease diagnosis and drug metabolism research.

This invention belongs to the field of bile acid detection technology, and discloses a sample pretreatment method for determining the content of bile acid subtypes and its application. The pretreatment method includes the following steps: S1, acidifying the sample to be tested with an acidifying agent to a pH of 2-4 to obtain an acidified sample; S2, eluting the acidified sample onto a mixed-mode anion exchange column to obtain an eluent; S3, evaporating the eluent and reconstituted with a rehydration solution to obtain the test sample. The test sample obtained by this pretreatment method can effectively eliminate or compensate for matrix interference when used for targeted analysis of bile acid subtypes by LC-MS / MS, thus effectively improving detection sensitivity.

The invention relates to the technical field of aquaculture feed, and provides a compound feed additive for improving fish sugar utilization rate and promoting growth, the compound feed additive comprises the following raw materials by weight: 0.1-0.14 part of chromium picolinate, 1.5-2.5 parts of vitamin C, 20-40 parts of amylase, 20-40 parts of protease, 10-20 parts of dimethyl-beta-propiothetin, 2-4 parts of bile acid, and 18-22 parts of a carrier. The compound feed additive provided by the invention has the beneficial effects that the blood sugar is regulated, and the sugar metabolism capability of fish bodies is improved; due to the use of the compound feed additive, energy supply caused by protein decomposition is reduced, so that the growth performance of the fishes and the utilization rate of the feed are improved; the low-temperature stress resistance of the fishes is improved, and the breeding negative influence caused by temperature change is reduced; the protein loss is reduced; the feed cost is reduced; and the culture benefit is improved.

The present invention provides means with which bile acids, phenols, indoles and organic acids contained in a sample can be stably preserved without cryopreservation of the sample. A sample preservation solution of the present invention is a sample preservation solution used for analyzing at least one component selected from the group consisting of bile acids, phenols, indoles and organic acids contained in a biological or environmental sample, containing at least the following (A) and (B): (A) condensed phosphate or polyoxyethylene sorbitan alkylate; and (B) guanidinium thiocyanate, Tris-HCl (pH 7 to 9), and EDTA.

The application relates to the technical field of medical detection, in particular to a detection kit for total bile acid and a detection kit for total bile acid. The application adds polyoxyethylene-polyoxypropylene copolymer, Span 40 and oxide in R1, and adds EDTA-Na2 and sodium bicarbonate in R2, so that the stability and precision of reagents are effectively improved, and the situation that a negative value is generated in the detection process is solved.

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

The application discloses a compound, a preparation method and a use for preparing a derivatization reagent, and belongs to the field of chemistry. The application claims a compound TMT-mAla-PP with a novel chemical structure and a preparation method and a use thereof. Compared with the same compound TMT-PP or TMT-Pro-PP in the prior art, the derivatization product obtained by using the TMT-mAla-PP provided by the application as a derivatization reagent for performing a derivatization reaction on a bile acid compound has a significantly better mass spectrometry response sensitivity. Therefore, the compound provided by the application can be used for preparing a derivatization reagent for a bile acid compound, and the derivatization reagent can perform derivatization modification on the bile acid compound before mass spectrometry detection of the bile acid compound, so that the detection performance of the mass spectrometry on the bile acid compound is significantly improved.

The invention discloses a traditional Chinese medicine composition and application thereof in medicine for improving non-alcoholic fatty liver, and the traditional Chinese medicine composition comprises pulvis fellis suis, pericarpium citri reticulatae, hawthorn and clostridium butyricum. On one hand, potential targets and pathways of drug diseases are determined in network pharmacological analysis, and on the other hand, in an in-vivo experiment, the drug provided by the invention improves obesity and impaired glucose tolerance caused by HFD, reduces the blood fat level, alleviates inflammation, protects the liver, alleviates liver fat vacuole deposition and fatty degeneration, and has a good application prospect. It is proved that the bile acid-hawthorn and pericarpium citri reticulatae-clostridium butyricum combination has prevention and treatment and protection effects on the HFD-induced non-alcoholic fatty liver disease.

The invention provides rhizoma alismatis purified polysaccharide as well as a preparation method, an identification method and application thereof, the rhizoma alismatis purified polysaccharide is a functional component with a novel structure in a traditional Chinese medicine rhizoma alismatis water extract obtained by further extraction and purification, the administration efficiency is effectively improved, and the pharmacodynamic substances are clarified; in-vivo and in-vitro experiments show that the polysaccharide can improve the antioxidant capacity of the liver and relieve inflammatory response; synthesis and metabolism of liver bile acid can be adjusted, cholestasis of the liver is relieved, and bile acid circulation is promoted so as to relieve acute liver injury caused by acetaminophen; the effect of promoting the recovery of liver injury patients is obvious; and the compound also can be used as prebiotics to improve the homeostasis of intestinal microorganisms and promote the synthesis of short-chain fatty acids so as to have beneficial effects on the liver.

The present invention addresses the problem of: developing a method capable of noninvasively sampling and analyzing intestinal mucosa bacteria; analyzing the intestinal bacteria, especially intestinal mucosa bacteria on the basis of the method; and developing a therapeutic method for diseases occurring in the intestinal tract for which therapeutic methods have not been established.　The inventors of the present invention have found that bacteria contained in a cotton swab (swab) sample on the feces surface exhibit a bacterial flora composition similar to that of bacteria existing in the intestinal mucosa; and, as a result of analysis based on the finding, have clarified that Adlercreutzia, which has not been reported until now as a mucosa-related bacterium, lives in the large intestinal mucosa layer, produces taurine, which is a strong anti-inflammatory compound, by the action of the bile acid-deconjugating enzyme, and alleviates enteritis, thereby completing the present invention. In other words, the present invention can provide a composition having an anti-inflammatory effect, which includes a bacterium of the genus Adlercreutzia, or a bile acid-deconjugating enzyme that is derived from a bacterium of the genus Adlercreutzia.

The present invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators with apical sodium-dependent bile acid transporter (ASBT) and / or hepatic bile acid transport (LBAT) inhibitory activity. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases, and liver diseases.

Provided is a compound that can be used as an antitumor agent and exhibits improved biocompatibility. The compound according to the present disclosure comprises a bile acid and a polymer chain. The polymer chain is formed from a biocompatible cationic polymer.

The present invention relates to the medical and food use of bile acid derivatives. Specifically, the present invention relates to the use of 3-oxoLCA in reducing oxidative stress and inflammation in pregnant mothers and their offspring. Specifically, the present invention relates to the use of 3-oxoLCA to reverse the effects of oxidative stress on pregnant mothers, in particular, to maintain fetal equal weight, significantly reduce placental and liver oxidative stress in pregnant mothers and the resulting inflammation or dysfunction of the placenta and liver, and to improve the intestinal flora imbalance of pregnant mothers. Further studies have found that 3-oxoLCA has long-term effects, in particular, can significantly reduce the effects of oxidative stress during pregnancy on oxidative stress and inflammation in the liver of offspring.

Provided herein are methods and compositions related to treating or preventing metabolic disorder.

The present application provides a compound of formula (I), or an optical isomer thereof, a pharmaceutically acceptable salt, a solvated form, or a prodrug. The compound may modulate NTCP function for the prevention and / or treatment of HBV / HDV and hepatitis virus-related diseases, bile acid-related cholestasis disorders, metabolic disorders, and / or liver diseases. Additionally, the present application relates to a pharmaceutical composition comprising such a compound and a method for modulating NTCP.

This invention discloses a *Lactobacillus plantarum* YBE2 and its applications. The *Lactobacillus plantarum* provided by this invention, which produces a high amount of extracellular polysaccharides primarily composed of rhamnose, can simultaneously degrade different types of bile salts, including specifically hydrolyzing glycocholic acid. It also exhibits cholesterol-lowering and acute inflammation-relieving effects. Furthermore, *Lactobacillus plantarum* YBE2 can reduce fat deposition in the abdomen of caged broilers, increase intramuscular fat, promote fatty acid deposition in muscles, and reduce plasma total bile acids, triglycerides, and low-density lipoprotein cholesterol. This significantly improves lipid metabolism and muscle quality in poultry, and can be widely applied in caged broiler farming to promote healthy poultry farming and improve farming efficiency.

The invention relates to aminoethyl thioesters of saturated carboxylic acids, of a short chain acid, and a bile acid, therapeutic compositions containing such aminoethyl thioesters, and a method of improving the health of an animal or of treating of ameliorating a health disorders in an animal by administering to the animal an effective amount of a therapeutic composition comprising an inventive aminoethyl thioester of a carboxylic acid.

The present application relates to a kind of fat powder for special aquaculture and its preparation method and application, the composition of the fat powder includes: compound oil, emulsifier, bile acid salt, lipase, antioxidant, fat-soluble vitamin, carrier material;The compound oil is composed of algal oil, deep sea fish oil, rice bran oil, 24 ℃ fractionated palm oil, refined coconut oil, soybean lecithin and medium-chain triglyceride.The present application is not simply mixed oil product, but is the comprehensive functional fat powder constructed around the growth, reproduction, resistance, intestinal health and meat quality of special aquatic animals, can simultaneously consider "promote growth, reduce fishy smell, enhance resistance, promote reproduction, protect intestinal tract, promote absorption" and multiple goals, with obvious system and uniqueness.

The present invention relates to a molecular association of a bile acid or a bile salt and a composition containing the same, and more specifically, to a skin-permeable formulation of deoxycholic acid, a lipolytic pharmacological agent, which has been developed as an external preparation rather than a conventional injection, and which dramatically improves patient compliance.

To provide a composition containing phenylbutyric acid compound and bile acid, and a method for processing the composition.SOLUTION: A composition contains: (a) approximately 15% to approximately 45w / w% of phenylbutyric acid compound; (b) approximately 5% to approximately 15w / w% of bile acid; (c) approximately 8% to approximately 24w / w% of dextrate; (d) approximately 1% to approximately 6w / w% of sugar alcohol; and (e) approximately 22% to approximately 35% of maltodextrin, where a weight ratio between the phenylbutyric acid compound and the bile acid is approximately 3:1.SELECTED DRAWING: Figure 1

This invention discloses a single-herb bezoar preparation based on an ancient prescription; an enteric-coated bezoar soft capsule and its preparation method. The enteric-coated bezoar soft capsule consists of a bezoar dispersion and an enteric-coated soft capsule shell. A sand mill is used to prepare bezoar powder into micron-sized particles with a particle size ≤100μm. The micron-sized bezoar powder is fully dispersed in a dispersion medium, thereby improving the solubility of bezoar. The single-herb bezoar preparation can improve the problem of inconsistent bezoar content in compound bezoar preparations. The process of preparing the ≤100μm micron-sized bezoar dispersion uses non-metallic grinding equipment, avoiding the catalytic reaction of metal ions during the preparation of micron-sized powder. Low-temperature grinding is also used to avoid denaturation of the heat-sensitive active substances in bezoar, better preserving its biological activity. The enteric-coated formulation prevents the drug from being released in the stomach until it reaches the small intestine, avoiding the precipitation of bilirubin and other bile acids in the acidic environment of the stomach, which would otherwise lead to insoluble solids and poor solubility.

The invention discloses a traditional Chinese medicine composition for treating gallstone and a preparation method thereof, and relates to the technical field of traditional Chinese medicine compositions, and the traditional Chinese medicine composition for treating gallstone is characterized by comprising the following components: lysimachia christinae hance, endothelium corneum gigeriae galli, lygodium japonicum, radix curcumae, corn stigma and szechwan chinaberry fruit. Clinical and experiments prove that the traditional Chinese medicine composition can effectively eliminate clinical symptoms of gallstone, and can correct liver function and dyslipidemia, relieve the inflammation level, regulate abnormal metabolism of cholesterol-bile acid, remarkably promote dissolution and discharge of gallstone and inhibit recurrence of gallstone. The traditional Chinese medicine composition not only can effectively prevent and treat gallstone and remarkably relieve clinical symptoms of patients, but also can reduce the treatment cost and avoid pain caused by operations, and has a wide application prospect.

The application belongs to the technical field of microorganisms, and discloses a bacillus amyloliquefaciens D189 with high yield of extracellular polysaccharide. The bacillus amyloliquefaciens D189 is preserved in China Center for Type Culture Collection on April 29, 2021, and the preservation number is CCTCC NO: M2021484. The bacillus amyloliquefaciens D189 provided in the application has high yield of extracellular polysaccharide, the yield of the crude extracellular polysaccharide EPS-OD is 131.31+ / -2.13 g / L after optimization, the extracellular polysaccharide EPS is obtained by purifying the crude EPS-OD through a DEAE ion exchange column, and the composition of the crude EPS-OD and the EPS is determined. The extracellular polysaccharide of the bacillus amyloliquefaciens D189 has good alpha-glucosidase inhibitory capacity and pancreatic lipase inhibitory capacity, and good total bile acid and cholesterol micelle binding capacity in vitro, so that the extracellular polysaccharide and the lipid-lowering and glucose-lowering product have good application prospects.

The application belongs to the technical field of biological processing, and specifically discloses a sea cucumber flower polypeptide with lipid-lowering efficacy as well as a preparation method and application thereof. The sea cucumber flower polypeptide with lipid-lowering efficacy is composed of short peptides with a molecular weight less than 1000 Da; the short peptides are one or more of GTGATGTF, FTGIVGSL, LAIGETEF, VGITDIESF, VDDEF and YDDVP. The application discloses a sea cucumber flower polypeptide with lipid-lowering efficacy as well as a preparation method and application thereof. The sea cucumber flower polypeptide has a significantly improved inhibition rate on cholesteryl esterase and pancreatic lipase, and has a stronger adsorption capacity on bile acid. The sea cucumber flower polypeptide does not contain the enzyme cutting sites of pepsin and trypsin, can resist secondary digestion and degradation after being taken into the human body, stably maintains structural integrity and biological activity, and solves the problem that traditional lipid-lowering peptides are easily destroyed in activity.

The invention relates to a compound feed additive used in the laying period of breeding hens and a preparation method thereof, and belongs to the technical field of breeding hens breeding and hatching. The invention discloses a compound feed additive. Comprising the following components in parts by weight: 15 to 25 parts of clostridium butyricum, 25 to 35 parts of bacillus subtilis, 12 to 18 parts of bacillus licheniformis, 5 to 15 parts of vitamin B family, 2 to 4 parts of choline dihydrogen citrate, 2 to 5 parts of herba epimedii extract, 0.2 to 0.4 part of nano L-selenomethionine, 4 to 6 parts of bile acid, 5 to 8 parts of yeast cell wall polysaccharide, 2 to 5 parts of organic zinc, 5 to 15 parts of trace elements and 1 to 3 parts of phytase. Through scientific proportioning and synergistic effect of multiple functional components, the feed improves intestinal health of breeding hens, improves reproductive performance, enhances immunity, promotes digestion and absorption of the breeding hens to nutrient substances in the feed, improves feed conversion rate and reduces feed-egg ratio.

The invention discloses a feed additive for rapidly improving metabolic syndrome of carnivorous aquatic animals. Every 1000g of the feed additive comprises the following components: 20 to 40g of tea polyphenol, 0.5 to 2g of nuciferine, 8 to 25g of ginkgetin, 3 to 8g of glycyrrhetinic acid, 0.5 to 1.5 g of sennoside, 5 to 10g of glutathione, 0.1 to 5g of ginsenoside, 0.1 to 0.5 g of bile acid, 1 to 5g of vitamin C, 0.1 to 0.5 g of vitamin E, 0.01 to 0.05 g of vitamin K and the balance of a carrier. The feed additive is prepared according to the principle of monarch, minister, assistant and guide, and can quickly improve the metabolic syndrome symptom of carnivorous aquatic animals. Experiments show that the additive can recover healthy appearance of the liver, regulate blood sugar and blood fat, enhance oxidation resistance and relieve inflammatory response within a short period of 3-4 days. The feed additive is safe, efficient, free of toxic and side effects, low in cost and suitable for various carnivorous aquatic animals such as micropterus salmoides, Chinese softshell turtles and sturgeons, an efficient and safe solution is provided for prevention and control of the metabolic syndrome of the aquatic animals, and the feed additive has good popularization value.

The present application belongs to the technical field of aquaculture, and particularly relates to a plant source composite preparation for reducing antibiotic residues in cultured aquatic products, and a preparation method and use method thereof. The plant source composite preparation comprises the following raw materials in parts by weight: 20.0-35.0 parts of a composite plant extract, 0.5-2.0 parts of glucose oxidase, and 0.8-3.0 parts of bile acid; wherein the composite plant extract comprises extract of dried orange peel, extract of licorice, extract of sea buckthorn, extract of sophora fruit, extract of mulberry leaf, extract of bupleurum, and extract of green tea. The plant source composite preparation is prepared by stepwise mixing, and then mixed with feed at a ratio of 0.4-1:100 and fed for 5-10 days, so as to accelerate the metabolism and excretion of antibiotics, shorten the drug holiday, and ensure the quality and safety of aquatic products.